Chinese expert consensus on the overall management of liver function in conversion therapy for liver cancer(2022 edition)  

作　　者：Qinghua Meng Zhengqiang Yang Zhenyu Zhu Juan Li Xinyu Bi Xiao Chen Chunyi Hao Zhen Huang Fei Li Xiao Li Guangming Li Yinmo Yang Yefan Zhang Haitao Zhao Hong Zhao Xu Zhu Jiye Zhu Jianqiang Cai The Liver Tumor Branch of the China International Exchange and Promotive Association for Medical and Healthcare(CPAM) The Gastrointestinal Cancer Multidisciplinary Cooperation Group of Cancer Hospital Chinese Academy of Medical Sciences&Peking Union Medical College The Liver Cancer Professional Committee of Chinese Medical Doctor Association 

机构地区：[1]Department of Hepatology,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China [2]Department of Interventional Radiology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [3]Department of Hepatobiliary Surgery,The Fifth Medical Center of PLA General Hospital,National Clinical Research Center for Infectious Diseases,Beijing 100039,China [4]Department of Hepatobiliary Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China [5]Department of Hepatobiliary Surgery,Peking University Cancer Hospital and Institute,Beijing 100142,China [6]Department of General Surgery,Xuanwu Hospital,Capital Medical University,Beijing 100053,China [7]Department of Hepatobiliary Surgery,Beijing Youan Hospital,Capital Medical University,Beijing 100054,China [8]Department of General Surgery,Peking University First Hospital,Beijing 100034,China [9]Department of Hepatobiliary Surgery,Peking Union Medical College Hospital,Beijing 100021,China [10]Department of Interventional Radiology,Peking University Cancer Hospital and Institute,Beijing 100142,China [11]Department of Hepatobiliary Surgery,Peking University People’s Hospital,Beijing 100044,China [12]不详

出　　处：《Chinese Medical Journal》2023年第24期2909-2911,共3页中华医学杂志（英文版）

摘　　要：Introduction Primary liver cancer is a significant health issue in China,where it ranks fourth in morbidity and second in mortality among all malignant tumors.[1-4]The 5-year overall survival rate of Chinese patients with liver cancer from 2012 to 2015 was only 12.2%for males and 13.1%for females.[5]Hepatocellular carcinoma(HCC)accounts for 75-85%of primary liver cancers.[6]Furthermore,most liver cancers are unresectable at diagnosis.To combat this,conversion therapy is used,which involves systematic treatments like anti-angiogenic drugs or molecular targeted therapy combined with immunotherapies,as well as locoregional treatments such as transcatheter arterial chemoembolization(TACE),hepatic artery infusion chemotherapy(HAIC),ablation therapy,and radiation therapy.The goal is to eliminate unresectable status and increase the chances of surgery.The reported 5-year survival rate after salvage surgery following tumor downstaging varied from 24.9-57%.

关 键 词：DRUGS INFUSION eliminate 

分 类 号：R735.7[医药卫生—肿瘤]